Teva Pharmaceutical Industries Limited
TEVA
$16.71
$0.382.33%
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 4.23B | 4.33B | 4.16B | 3.82B | 4.46B |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 4.23B | 4.33B | 4.16B | 3.82B | 4.46B |
| Cost of Revenue | 2.11B | 2.18B | 2.14B | 2.05B | 2.04B |
| Gross Profit | 2.12B | 2.15B | 2.02B | 1.77B | 2.42B |
| SG&A Expenses | 952.00M | 924.00M | 939.00M | 886.00M | 902.00M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | 28.00M | -19.00M | -1.00M | -17.00M | 36.00M |
| Total Operating Expenses | 3.34B | 3.33B | 3.35B | 3.16B | 3.21B |
| Operating Income | 893.00M | 1.00B | 817.00M | 660.00M | 1.25B |
| Income Before Tax | -247.00M | -321.00M | -245.00M | -471.00M | 508.00M |
| Income Tax Expenses | 28.00M | 69.00M | 630.00M | -52.00M | 41.00M |
| Earnings from Continuing Operations | -275.00M | -390.00M | -875.00M | -419.00M | 467.00M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | 58.00M | -47.00M | 29.00M | 280.00M | -4.00M |
| Net Income | -217.00M | -437.00M | -846.00M | -139.00M | 463.00M |
| EBIT | 893.00M | 1.00B | 817.00M | 660.00M | 1.25B |
| EBITDA | 1.16B | 1.26B | 1.08B | 932.00M | 1.52B |
| EPS Basic | -0.19 | -0.39 | -0.75 | -0.12 | 0.41 |
| Normalized Basic EPS | 0.42 | 0.36 | 0.34 | 0.48 | 0.56 |
| EPS Diluted | -0.19 | -0.39 | -0.75 | -0.12 | 0.40 |
| Normalized Diluted EPS | 0.42 | 0.36 | 0.34 | 0.48 | 0.55 |
| Average Basic Shares Outstanding | 1.13B | 1.13B | 1.13B | 1.12B | 1.12B |
| Average Diluted Shares Outstanding | 1.13B | 1.13B | 1.13B | 1.12B | 1.14B |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
